March 10, 2010 Nevada Senate Bill 4 was signed by Governor Jim Gibbons on March 6, 2010. It adds the three new drug classes to the Medicaid preferred drug list (PDL) and outlines grandfathering procedures for particular drugs. It goes into effect June 30, 2010; people taking brand-name atypical and typical antipsychotic medications to treat mental illness, anticonvulsant medications, and anti-diabetic medications will have continued access to those medications. No prior authorization will be required if the patient maintains continuous Medicaid eligibility and continues to take the medication. After June 30, 2010, prior authorization for new clinical uses . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Nevada Senate Bill 4; Adding Antipsychotic Medications to the Medicaid Preferred Drug List

March 10, 2010 Nevada Senate Bill 4 was signed by Governor Jim Gibbons on March 6, 2010. It adds the three new drug classes to the Medicaid preferred drug list (PDL) and outlines grandfathering procedures for particular drugs. It goes into effect June 30, 2010; people taking brand-name atypical and typical antipsychotic medications to treat mental illness, anticonvulsant medications, and anti-diabetic medications will have continued access to those medications. No prior authorization will be required if the patient maintains continuous Medicaid eligibility and continues to take the medication. After June 30, 2010, prior authorization for new clinical uses . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.